Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older

Trial Identifier: VBT00001
Sponsor: Sanofi
Start Date: November 2024
Primary Completion Date: April 2026
Study Completion Date: April 2026
Condition: Influenza Immunisation; COVID-19 Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
United States, Alabama BIRMINGHAM, Alabama, United States, 35211
United States, Arizona TUCSON, Arizona, United States, 85741
United States, Georgia ATLANTA, Georgia, United States, 30328
United States, Illinois CHICAGO, Illinois, United States, 60602
United States, Missouri CREVE COEUR, Missouri, United States, 63141
United States, Texas DALLAS, Texas, United States, 75234
United States, Texas SAN ANTONIO, Texas, United States, 78229
UNITED STATES, Alabama Huntsville, Alabama, UNITED STATES, 35802-2568
UNITED STATES, Florida THE VILLAGES, Florida, UNITED STATES, 32162
UNITED STATES, New York NEW YORK, New York, UNITED STATES, 10017
UNITED STATES, Texas AUSTIN, Texas, UNITED STATES, 78705
UNITED STATES, Utah SALT LAKE CITY, Utah, UNITED STATES, 84106